COMP <GO>
HCM vs UNH // RETURN ON INVESTED CAPITAL (ROIC)
HUTCHMED (China) Limited (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: HCM 3
— UNH 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: UNH
LAST: $13.59 (+2.03%) • MKT CAP: $2.37B
roic
-2.50%
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
roic
11.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HCM VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HCM | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.57% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -2.50% | 11.47% | -13.97 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.32% | 6.48% | -9.80 | UNH | /fcf-yield <GO> |
| Operating Margin | -7.10% | 4.82% | -11.92 | UNH | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 3.14% | +64.86 | HCM | /net-margins <GO> |
| Revenue Growth (YoY) | -13.00% | 6.46% | -19.46 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.63 | 3.12 | +0.51 | HCM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.1 | 59.2 | -18.13 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 4.8x | 17.1x | -12.29 | HCM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.37B | $368.83B | -$366.46B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HCM REV | UNH REV | HCM GROSS % | UNH GROSS % | HCM FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $548.5M | $447.57B | 38.7% | 88.7% | -$78.8M | $16.07B |
| FY 2024 | $630.2M | $400.28B | 44.6% | 88.3% | -$17.4M | $20.70B |
| FY 2023 | $838.0M | $371.62B | — | 89.6% | $219.3M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HCM // BETA —
UNH // BETA 0.33